ATA3219
ATA3219-NHL-103
Phase 1 small_molecule terminated
Quick answer
ATA3219 for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a Phase 1 program (small_molecule) at Atara Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Atara Biotherapeutics
- Indication
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated